Image and Dosimetry Related Research of Department of Medical Physics, Cross Cancer Institute

计划入组 40 人 · 首次发布于 2006 年 4 月 14 日

Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014

计划入组 115 人 · 首次发布于 2013 年 1 月 9 日

Pharmacist Discharge Medication Reconciliation Study

计划入组 50 人 · 首次发布于 2010 年 10 月 22 日

GRP78 inhibitors (Amgen/Cancer Research Technology/Institute of Cancer Research)

MRK-560

DNA vaccine (National Institutes of Health/Karolinska Institutet)

Duke Cancer Institute

United States

CANCER INSTITUTE (WIA)

India

Barts Cancer Institute

United Kingdom

Alberta Cancer Foundation Invests $35-Million to Power Cancer Clinical Trials Across the Province

Onco-Innovations Partners with University of Alberta to Advance PNKP Inhibitor Research for Glioblastoma Treatment

Real-World Data Confirms Predictors of Exceptional Response to HER2-Targeted Therapy in Metastatic Breast Cancer